Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Trkola

Showing results (31-40 of 42) with videos related to

Pageof 5
Sort By:
The Journal of Infectious Diseases|July 7, 2000
Single-dose safety, pharmacology, and antiviral activity of the human immunodeficiency virus (HIV) type 1 entry inhibitor PRO 542 in HIV-infected adultsJ M Jacobson, I Lowy, C V Fletcher, et al.
Journal of Virology|January 7, 1998
Amino-terminal substitutions in the CCR5 coreceptor impair gp120 binding and human immunodeficiency virus type 1 entryT Dragic, A Trkola, S W Lin, et al.
The Journal of Clinical Investigation|September 24, 1999
HIV-1-specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapyG M Ortiz, D F Nixon, A Trkola, et al.
Journal of Virology|January 28, 1998
Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccinesR I Connor, B T Korber, B S Graham, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 19, 2001
SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivoJ M Strizki, S Xu, N E Wagner, et al.
Open Forum Infectious Diseases|July 17, 2015
Increases in Condomless Sex in the Swiss HIV Cohort StudyRoger D Kouyos, Barbara Hasse, Alexandra Calmy, et al.
Open Forum Infectious Diseases|March 4, 2015
Obesity Trends and Body Mass Index Changes After Starting Antiretroviral Treatment: The Swiss HIV Cohort StudyBarbara Hasse, Martin Iff, Bruno Ledergerber, et al.
Open Forum Infectious Diseases|June 3, 2015
Incident Hepatitis C Virus Infections in the Swiss HIV Cohort Study: Changes in Treatment Uptake and Outcomes Between 1991 and 2013Gilles Wandeler, Marion Schlauri, Marie-Eve Jaquier, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 11, 2016
Emergence of Acquired HIV-1 Drug Resistance Almost Stopped in Switzerland: A 15-Year Prospective Cohort AnalysisAlexandra U Scherrer, Viktor von Wyl, Wan-Lin Yang, et al.
BMC Infectious Diseases|September 28, 2011
High specificity of line-immunoassay based algorithms for recent HIV-1 infection independent of viral subtype and stage of diseaseJörg Schüpbach, Leslie R Bisset, Stephan Regenass, et al.
Pageof 5

Showing results (31-40 of 42) with videos related to

Sort By:
Pageof 5
The Journal of Infectious Diseases|July 7, 2000
Single-dose safety, pharmacology, and antiviral activity of the human immunodeficiency virus (HIV) type 1 entry inhibitor PRO 542 in HIV-infected adultsJ M Jacobson, I Lowy, C V Fletcher, et al.
Journal of Virology|January 7, 1998
Amino-terminal substitutions in the CCR5 coreceptor impair gp120 binding and human immunodeficiency virus type 1 entryT Dragic, A Trkola, S W Lin, et al.
The Journal of Clinical Investigation|September 24, 1999
HIV-1-specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapyG M Ortiz, D F Nixon, A Trkola, et al.
Journal of Virology|January 28, 1998
Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccinesR I Connor, B T Korber, B S Graham, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 19, 2001
SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivoJ M Strizki, S Xu, N E Wagner, et al.
Open Forum Infectious Diseases|July 17, 2015
Increases in Condomless Sex in the Swiss HIV Cohort StudyRoger D Kouyos, Barbara Hasse, Alexandra Calmy, et al.
Open Forum Infectious Diseases|March 4, 2015
Obesity Trends and Body Mass Index Changes After Starting Antiretroviral Treatment: The Swiss HIV Cohort StudyBarbara Hasse, Martin Iff, Bruno Ledergerber, et al.
Open Forum Infectious Diseases|June 3, 2015
Incident Hepatitis C Virus Infections in the Swiss HIV Cohort Study: Changes in Treatment Uptake and Outcomes Between 1991 and 2013Gilles Wandeler, Marion Schlauri, Marie-Eve Jaquier, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 11, 2016
Emergence of Acquired HIV-1 Drug Resistance Almost Stopped in Switzerland: A 15-Year Prospective Cohort AnalysisAlexandra U Scherrer, Viktor von Wyl, Wan-Lin Yang, et al.
BMC Infectious Diseases|September 28, 2011
High specificity of line-immunoassay based algorithms for recent HIV-1 infection independent of viral subtype and stage of diseaseJörg Schüpbach, Leslie R Bisset, Stephan Regenass, et al.
Pageof 5